Head and neck cancers account for approximately 3.0% of all new cancer diagnoses. 18F-FDG PET/CT plays an important role in the initial staging of these cancers, especially in the detection of nodal and distant metastatic disease, outperforming conventional imaging techniques. It helps identify occult primary tumors and synchronous second primary malignancies. PET/CT findings can lead to treatment plan alterations both in surgical and primary or adjuvant chemoradiation plans. High negative predictive value at treatment response assessment provides valuable prognostic implications. PET/CT can predict outcomes at baseline and during or after treatment.
头颈部癌症约占所有新发癌症诊断的3.0%。18F-FDG PET/CT在这些癌症的初始分期中发挥着重要作用,尤其在淋巴结和远处转移性疾病的检测方面优于传统影像学技术。该技术有助于识别隐匿性原发肿瘤及同步发生的第二原发恶性肿瘤。PET/CT的发现可导致手术治疗方案及原发性或辅助性放化疗方案的调整。其在治疗反应评估中具有较高的阴性预测值,为预后判断提供了重要依据。PET/CT可在基线期、治疗期间及治疗后对疾病转归进行预测。
Use of FDG PET for Staging and Re-Staging of Head and Neck Squamous Cell Carcinoma